Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study.
Valerio GristinaNadia BarracoMaria La MantiaLuisa CastellanaLavinia InsalacoMarco BonoAlessandro PerezDelia SardoSara IngugliaFederica IaconoSofia CutaiaTancredi Didier Bazan RussoEdoardo FranciniAntonio RussoGiuseppe BadalamentiAntonio RussoAntonio GalvanoViviana BazanPublished in: Cancers (2022)
Our real-world study demonstrates that quantitative changes in cfDNA values correlated with responses to therapy and relapse of disease in treatment-naïve patients with advanced NSCLC undergoing TKI- and IO-based treatments.